Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is usually treated with surgery and chemotherapy. However, a small group of patients can also be helped by treatment with tyrosine kinase inhibitors ...
Mar 20, 2012
0
0
In the late 1970s, the relationship between the c-Src gene and cancer was discovered. The first oncogene was identified. Since then, c-Src has been found to be overactivated in half of colon, liver, lung, breast, prostate ...
Oct 31, 2023
0
31
Northwestern Medicine investigators have discovered the mechanisms by which a particular protein promotes cancer cell proliferation and survival in acute myeloid leukemia (AML), according to a Northwestern Medicine study ...
Nov 4, 2022
0
11
Dasatinib, a drug that often is used to treat certain types of leukemia, may have antidiabetic effects comparable to medications used to treat diabetes, and with more research may become a novel therapy for diabetic patients, ...
Nov 9, 2021
0
58
Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journal ...
Jun 28, 2011
0
0
The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current ...
Feb 5, 2016
0
155
Recent findings in the laboratory of University of Kentucky Markey Cancer Center researcher Christine Brainson, Ph.D., could lead to promising treatments for two molecular subtypes of lung cancer.
Feb 10, 2022
0
11
A team with members affiliated with several institutions in the U.S. has found that disabling the gene responsible for the production of the protein tyrosine phosphatase D (PTPRD) caused test mice to self-administer less ...
The effectiveness of cancer treatment is often hampered by cancer cells being heterogeneous. This is the case for EGFR-mutated lung cancer: drugs based on biomolecules of a type known as tyrosine kinase inhibitor (TKI) have ...
Oct 5, 2020
0
6
Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report at the first ESMO Asia 2015 Congress in Singapore.
Dec 21, 2015
0
1
